|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
August 2005FeaturesCover Story Keeping Up With Genetic AdvancesThe emergence of molecular medicine and diagnostics
is bringing sweeping changes to the delivery of health care. Practitioners will begin to see patients in a completely new way. For clinicians who don’t know what they don’t know, change will be a challenge. Diagnostics Plans Still Reluctant To Embrace Many Genetic Screening TestsQuestions about cost effectiveness are paramount as payers slowly integrate new diagnostic tools. Evidence to help them make careful coverage determinations is often incomplete. Regulation 4 Regulatory Issues To WatchThe future of biotechnology will be determined largely by biologic follow-ons, pharmacogenomics, HIPAA, and the FDA’s direction on safety. Progress on many of these issues is painstakingly slow. Medicare Payment Differential Could Threaten Medicare Drug Benefit.Inconsistencies and competing interests between Medicare Parts B and D could create perverse incentives that lead to suboptimal outcomes. Technology Tapping Into the Value of EHRs.Electronic health records hold vast potential for streamlining patient recruitment for clinical trials and improving outcomes research. Reimbursement Strategies for the Day After LaunchThe author presents case studies on ensuring patients access to new biologic products, even when payment is down and operating expenses are up. DepartmentsOpeners Knowledge Is Its Own Reward
Michael D. Dalzell Editorial BIO 2005 Philadelphia
David B. Nash, MD, MBA Washington Watch FDA Guidances on Trial Endpoints Could Change Drug Development
John Carroll DrugTrack Approvals, FDA Actions, Clinical Trials
Bob Carlson Diagnostics and Devices Better HIV Monitoring Capabilities Help To Minimize Therapeutic Costs
Bob Carlson Biotech Business Biotech-Pharma Partnerships Reach All-Time High
Amanda Brower In the Pipeline Biologics Lead Trend in Drug Spending in 2004 |
|||||